Results
While feasible and safe, injection pain of i.d. adalimumab was higher
compared to s.c. adalimumab (35.4 vs. 7.9 on a 101-point VAS scale).
Initial absorption rate and bioavailability were higher after i.d.
adalimumab (Tmax=95h(47-120); F=129%(6.46%)) compared
to s.c. adalimumab (Tmax=120h(96-221)). In 50% and 83%
of the subjects anti-adalimumab antibodies were detected after i.d. and
s.c. adalimumab, respectively. We observed statistically significantly
more erythema and skin perfusion after i.d. adalimumab, compared to s.c.
adalimumab and placebo injections (p<0.0001). Cytokine
secretion after whole blood LPS challenge was comparable between
administration routes.